In several large-scale, placebo-controlled clinical trials, prasterone reduced the risk of autoimmune flare in women with SLE.<\/p>\n\n\n\n
A multi-center, double-blinded, placebo-controlled study used a study population (n = 381) balanced to reflect the racial mix of the SLE patient population in the United States and treatment for up to twelve months.[1]<\/a> Treatment reduced the risk of flare viz<\/em> placebo. The effect was most easily observed in women with active (SLEDAI >2) SLE: the percentage of such patients experiencing at least one flare during the study period was 34% (50\/146) in the placebo group and 25% (36\/147) in the treatment group (p<\/em> = 0.07). The data similarly showed a ","protected":false},"excerpt":{"rendered":" In several large-scale, placebo-controlled clinical trials, prasterone reduced the risk of autoimmune flare in women with SLE. A multi-center, double-blinded, placebo-controlled study used a study population (n = 381) balanced to reflect the racial mix of the SLE patient population in the United States and treatment for up to twelve months.[1] Treatment reduced the risk … <\/p>\n